Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

March 31, 2006

Study Completion Date

May 31, 2006

Conditions
Leukemia, Lymphocytic, Chronic
Interventions
DRUG

ONTAK

Trial Locations (14)

3002

Peter MacCallum Cancer Institute, East Melbourne

3199

Oncology Day Unit, Frankston Hospital, Frankston

5500

Montecaseros, Mendoza

10021

Weill Medical College of Cornell University/New York Presbyterian Hospital, New York

60612

Rush-Presbyterian St. Luke's Cancer Center, Chicago

77030

University of Texas, M.D. Anderson Cancer Center, Houston

92708

Pacific Coast Hematology/Oncology Medical Group, Inc., Fountain Valley

92093-0663

UCSD School of Medicine, La Jolla

74605-070

Hospital Araujo Jorge - Associacao de Combate ao Cancer em Goias, Goiânia

80060-900

Hospital de Clinicas da Universidade Federal do Parana, Curitiba

21941-590

Universidade Federal do Rio de Janeiro - Hospital Universitario Clementino Fraga Filho, Rio de Janeiro

14784-400

Hospital de Cancer de Barretos - Fundacao Pio XII, Barretos

05403-000

Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, São Paulo

H3T 1E2

Sir Mortimer B. Davis - Jewish General Hospital, Montreal

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT00055146 - Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) | Biotech Hunter | Biotech Hunter